Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer
- PMID: 28903450
- PMCID: PMC5589689
- DOI: 10.18632/oncotarget.17184
Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer
Abstract
Colorectal cancer (CRC) has been the fourth leading cause of cancer-related mortality worldwide. Owing to clonal evolution and selection, CRC treatment needs multimodal therapeutic approaches and due monitoring of tumor progression and therapeutic efficacy. Liquid biopsy, involving the use of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes, may offer a promising noninvasive alternative for diagnosis and for real-time monitoring of tumor evolution and therapeutic response compared to traditional tissue biopsy. Monitoring of the disease processes can enable clinicians to readily adopt a strategy based on optimal therapeutic decision-making. This article provides an overview of the significant advances and the current clinical and biological significance of CTCs, ctDNA, and exosomes in CRC, as well as a comparison of the main merits and demerits of these three components. The hurdles that need to be resolved and potential directions to be followed with respect to liquid biopsies for detection and therapy of CRC are also discussed.
Keywords: circulating tumor DNA (ctDNA); circulating tumor cells (CTCs); colorectal cancer (CRC); exosomes; liquid biopsy.
Conflict of interest statement
CONFLICTS OF INTEREST The authors declare no conflict of interests.
Figures
Similar articles
-
Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer.Mol Cancer. 2022 Mar 25;21(1):86. doi: 10.1186/s12943-022-01556-2. Mol Cancer. 2022. PMID: 35337361 Free PMC article. Review.
-
Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons.Curr Colorectal Cancer Rep. 2016 Jun;12(3):151-161. doi: 10.1007/s11888-016-0320-y. Epub 2016 Apr 7. Curr Colorectal Cancer Rep. 2016. PMID: 27516729 Free PMC article.
-
Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.Oncotarget. 2016 Dec 20;7(51):85349-85364. doi: 10.18632/oncotarget.13350. Oncotarget. 2016. PMID: 27863403 Free PMC article.
-
Liquid Biopsy in Oral Cancer.Int J Mol Sci. 2018 Jun 8;19(6):1704. doi: 10.3390/ijms19061704. Int J Mol Sci. 2018. PMID: 29890622 Free PMC article. Review.
-
Detection and clinical significance of circulating tumor cells in colorectal cancer.Biomark Res. 2021 Nov 19;9(1):85. doi: 10.1186/s40364-021-00326-4. Biomark Res. 2021. PMID: 34798902 Free PMC article. Review.
Cited by
-
Tumor stem cells fuse with monocytes to form highly invasive tumor-hybrid cells.Oncoimmunology. 2020 Jun 16;9(1):1773204. doi: 10.1080/2162402X.2020.1773204. Oncoimmunology. 2020. PMID: 32923132 Free PMC article.
-
The Role of Tumor-Derived Exosomes in the Abscopal Effect and Immunotherapy.Life (Basel). 2021 Apr 23;11(5):381. doi: 10.3390/life11050381. Life (Basel). 2021. PMID: 33922480 Free PMC article. Review.
-
Isolated Metastases to Multiple Genital Organs: a Curious Case of Metachronous Spread of Carcinoma Colon.Indian J Surg Oncol. 2019 Jun;10(2):321-323. doi: 10.1007/s13193-018-0855-2. Epub 2019 Jan 4. Indian J Surg Oncol. 2019. PMID: 31168256 Free PMC article. No abstract available.
-
Nanotechnology in emerging liquid biopsy applications.Nano Converg. 2021 May 2;8(1):13. doi: 10.1186/s40580-021-00263-w. Nano Converg. 2021. PMID: 33934252 Free PMC article. Review.
-
Exosomes as smart drug delivery vehicles for cancer immunotherapy.Front Immunol. 2023 Jan 17;13:1093607. doi: 10.3389/fimmu.2022.1093607. eCollection 2022. Front Immunol. 2023. PMID: 36733388 Free PMC article. Review.
References
-
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917. - PubMed
-
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. - PubMed
-
- Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383:1490–502. - PubMed
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. - PubMed
-
- Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714–26. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources